BioSpace News Archive

Viewpoint Molecular Targeting, Inc., a radiopharmaceutical company developing precision lead-212-based α-particle oncology therapeutics and complementary diagnostic imaging agents, announced that the U.S. Food and Drug Administration has cleared an Investigational New Drug application to commence a Phase 1 imaging study of VMT-

MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, will present at the H.C. Wainwright 23rd Annual Global Investment Conference being held virtually September 13-15, 2021.

NGMedical, a German medical device manufacturer exclusively focused on creating innovative technologies for spinal application announces first operations of its purely additively manufactured titanium cervical BEE® cage.

Centessa Pharmaceuticals plc today announced positive topline results from the Phase 2a part of AP-0101, the six-month repeat dose portion of its ongoing first-in-human proof-of-concept study evaluating SerpinPC in severe hemophilia A and B patients.

Diffusion Pharmaceuticals Inc. today announced that Robert Cobuzzi, Jr., Ph.D., Chief Executive Officer, has issued a Letter to Shareholders.

Enveric Biosciences today announced that Dr. Joseph Tucker, MagicMed Industries’ (“MagicMed”) Chief Executive Officer, is scheduled to present at the H.C. Wainwright 23rd Annual Global Investment Conference and Virtual Gravitas Health Reimagined Investor Day.

- Biohaven presenting 17 abstracts, including three late-breaking abstracts and four oral presentations, highlighting the efficacy and safety of Nurtec ODT as both an acute and preventive treatment of migraine

Crescita Therapeutics Inc. is pleased to announce that it has entered into a distribution agreement with Obagi Cosmeceuticals LLC (“Obagi”) for the exclusive rights to promote, distribute and sell the Obagi Medical ® product line in Canada.

BrainsWay Ltd., a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, announced that Christopher von Jako, Ph.D., President and Chief Executive Officer, will present and participate in one-on-one investor meetings at two investment conferences during the month of September.

Enlivex Therapeutics Ltd. today announced that Company management will present a corporate overview at the H.C. Wainwright 23rd Annual Global Investment Conference, being held virtually September 13-15, 2021.